Abstract
Purpose
Photodynamic therapy (PDT) is a promising noninvasive treatment, which has been approved by the US Food and Drug Administration for the treatment of localized tumors. With the aim to select an appropriate photosensitizer for tumor treatment in PDT, the antitumor effect of a novel chlorin-based photosensitizer, meso-tetra (3-morphlinomethyl-4-methoxyphenyl) chlorin (TMMC) (Fig. 1a) on two types of human malignant tumor cells in vitro and a esophageal cancer model in nude mice, was evaluated in the present paper.
Chemical structure and spectrum properties of TMMC in DMF. a Chemical structure of TMMC in DMF. b UV–Vis absorption spectrum of TMMC in DMF. Its maximum absorbance is at 423 nm, and at 527, 555, 600, 655 nm and 712 nm, also it has absorption. c Emission spectrum of TMMC, which was excited at 514 nm, and its peaks were at 656 and 720 nm. d The matrix of excitation and emission spectra (Ex: 300–550 nm, Em: 600–780 nm)
Methods
The efficiency of TMMC–PDT in vitro was analyzed by MTT assay and clonogenic assay. The intracellular distribution of photosensitizers was detected with laser scanning confocal microscopy. The accumulation of TMMC in human malignant tumor cells was measured by Fluorescence Spectrometer, and the pathway of cell death was analyzed by flow cytometry. Eca-109 tumor model was used to evaluate the antitumor effects of TMMC-mediated PDT. And the singlet oxygen quantum yield of TMMC was also measured using DPBF as substrate.
Results
TMMC shows a singlet oxygen quantum yield of 0.59 and displays a characteristic long wavelength absorption peak at 655 nm. The accumulation of TMMC increased in time-dependent manner, and it was found in cytoplasm and nuclear membranes. TMMC–PDT induced cell death by the major death pathway of necrosis and significantly reduced the growth of Eca-109 tumors in nude mice (180 mW/cm2, 120 J/cm2).
Conclusion
The studies suggest that TMMC is an effective photosensitizer for PDT to tumors. Therefore, TMMC has great potentials for tumor treatment in PDT and deserves further investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ashen-Garry D, Selke M (2013) Singlet oxygen generation by cyclometalated complexes and applications. Photochem Photobiol. doi:10.1111/php.12211
Buytaert E, Dewaele M, Agostinis P (2007) Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776(1):86–107. doi:10.1016/j.bbcan.2007.07.001
Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, Pogue BW, Hasan T (2010) Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 110(5):2795–2838. doi:10.1021/cr900300p
Cheng Y, C. Samia A, Meyers JD, Panagopoulos I, Fei B, Burda C (2008) Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc 130(32):10643–10647. doi:10.1021/ja801631c
Chin W, Lau W, Cheng C, Olivo M (2004) Evaluation of Hypocrellin B in a human bladder tumor model in experimental photodynamic therapy: biodistribution, light dose and drug-light interval effects. Int J Oncol 25(3):623–629
Dewaele M, Verfaillie T, Martinet W, Agostinis P (2010) Death and survival signals in photodynamic therapy. Methods Mol Biol 635:7–33. doi:10.1007/978-1-60761-697-9_2
Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3(5):380–387. doi:10.1038/nrc1071
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90(12):889–905
Fien SM, Oseroff AR (2007) Photodynamic therapy for non-melanoma skin cancer. J Natl Compr Canc Netw 5(5):531–540
Gerlier D, Thomasset N (1986) Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 94(1–2):57–63
Hamblin MR, Miller JL, Rizvi I, Ortel B, Maytin EV, Hasan T (2001) Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer. Cancer Res 61(19):7155–7162
Hopper C (2000) Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol 1:212–219
Howard JA (1976) The new wilderness. The Journal of the American College of Dentists 43 (1):15–22, 32
Huang Z (2005) A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 4(3):283–293
Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6(5):513–519. doi:10.1038/74994
Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86(1):147–157
Lovell JF, Liu TW, Chen J, Zheng G (2010) Activatable photosensitizers for imaging and therapy. Chem Rev 110(5):2839–2857. doi:10.1021/cr900236h
Ochsner M (1997) Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol, B 39(1):1–18
Redmond RW, Gamlin JN (1999) A compilation of singlet oxygen yields from biologically relevant molecules. Photochem Photobiol 70(4):391–475
Reiners JJ Jr, Agostinis P, Berg K, Oleinick NL, Kessel D (2010) Assessing autophagy in the context of photodynamic therapy. Autophagy 6(1):7–18
Rello-Varona S, Stockert JC, Canete M, Acedo P, Villanueva A (2008) Mitotic catastrophe induced in HeLa cells by photodynamic treatment with Zn(II)-phthalocyanine. Int J Oncol 32(6):1189–1196
Senge MO, Brandt JC (2011) Temoporfin (Foscan(R), 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)–a second-generation photosensitizer. Photochem Photobiol 87(6):1240–1296. doi:10.1111/j.1751-1097.2011.00986.x
Silva EF, Serpa C, Dabrowski JM, Monteiro CJ, Formosinho SJ, Stochel G, Urbanska K, Simoes S, Pereira MM, Arnaut LG (2010) Mechanisms of singlet-oxygen and superoxide-ion generation by porphyrins and bacteriochlorins and their implications in photodynamic therapy. Chemistry 16(30):9273–9286. doi:10.1002/chem.201000111
Stockert JC, Canete M, Juarranz A, Villanueva A, Horobin RW, Borrell JI, Teixido J, Nonell S (2007) Porphycenes: facts and prospects in photodynamic therapy of cancer. Curr Med Chem 14(9):997–1026
Triesscheijn M, Baas P, Schellens JH, Stewart FA (2006) Photodynamic therapy in oncology. Oncologist 11(9):1034–1044. doi:10.1634/theoncologist.11-9-1034
Wagner A, Kiesslich T, Neureiter D, Friesenbichler P, Puespoek A, Denzer UW, Wolkersdorfer GW, Emmanuel K, Lohse AW, Berr F (2013) Photodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfin. Photochem Photobiol Sci 12(6):1065–1073. doi:10.1039/c3pp25425a
Yan YJ, Zheng MZ, Chen ZL, Yu XH, Yang XX, Ding ZL, Xu L (2010) Studies on preparation and photodynamic mechanism of chlorin P6-13,15-N-(cyclohexyl)cycloimide (Chlorin-H) and its antitumor effect for photodynamic therapy in vitro and in vivo. Bioorg Med Chem 18(17):6282–6291. doi:10.1016/j.bmc.2010.07.027
Yow CM, Chen JY, Mak NK, Cheung NH, Leung AW (2000) Cellular uptake, subcellular localization and photodamaging effect of temoporfin (mTHPC) in nasopharyngeal carcinoma cells: comparison with hematoporphyrin derivative. Cancer Lett 157(2):123–131
Acknowledgments
This work was supported by Chinese National Natural Science Foundation (21372042, 81101298), Foundation of Shanghai government (13431900700, 13430722300, 13ZR1441000, 13ZR1440900), and Foundation of Yiwu Science and Technology Bureau (2011-G1-15).
Conflict of interest
We declare that we have no conflict of interest in relation to this article exists.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, LJ., Bian, J., Bao, LL. et al. Photosensitizing effectiveness of a novel chlorin-based photosensitizer for photodynamic therapy in vitro and in vivo. J Cancer Res Clin Oncol 140, 1527–1536 (2014). https://doi.org/10.1007/s00432-014-1717-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1717-0